Advanced search
Publication Cover
Journal of Medical Economics Volume 19, 2016 - Issue 8
Submit an article Journal homepage
927
Views
13
CrossRef citations to date
0
Altmetric
Immunology

Cost-minimization analysis of sublingual immunotherapy versus subcutaneous immunotherapy for house dust mite respiratory allergic disease in Denmark

Steen RønborgAllergi-og Lungeklinikken, Valby, Denmark;
,
Claus R. JohnsenDepartment of Dermato-Allergology, Copenhagen University Hospital, Gentofte, Denmark;
,
Sune TheilgaardENT, Esbjerg, Denmark;
,
Anders WintherGP, Birkerød, Denmark;
,
Julie Hahn-PedersenALK, Hørsholm, Denmark; Correspondence[email protected]
,
Jakob Nørgaard AndreasenALK, Hørsholm, Denmark;
&
Jens OlsenHealth Economics Department, Incentive, Holte, Denmark
 show all
Pages 735-741 | Received 11 Jan 2016, Accepted 23 Feb 2016, Published online: 16 Mar 2016

Citations (13)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Giorgio Ciprandi & Maria Angela Tosca. (2021) House dust mites–driven allergic rhinitis: could its natural history be modified?. Expert Review of Clinical Immunology 17:2, pages 109-114.
Read now
Howraman Meteran & Vibeke Backer. (2019) SQ house dust mite sublingual immunotherapy for the treatment of adults with house dust mite-induced allergic rhinitis. Expert Review of Clinical Immunology 15:11, pages 1127-1133.
Read now

Articles from other publishers (11)

Steen M. Rønborg, Tobias Sydendal Grand, Henrik Brandi & Richard F. Pollock. (2022) ITULAZAX ® versus Alutard SQ ® in the treatment of allergic rhinitis induced by pollen from the birch homologous group: A cost‐minimization modeling analysis from the Danish societal perspective . Clinical and Translational Allergy 12:11.
Crossref
Anne K. Ellis, Rémi Gagnon, Eva Hammerby, Julia Shen & Sheena Gosain. (2021) Sublingual immunotherapy tablet: a cost-minimizing alternative in the treatment of tree pollen-induced seasonal allergic rhinitis in Canada. Allergy, Asthma & Clinical Immunology 17:1.
Crossref
D. Caimmi & P. Demoly. (2021) Recommandations pour la prescription de l’immunothérapie allergénique et le suivi du patient — Questions développées et revue de la littérature. Revue Française d'Allergologie 61:1, pages 35-56.
Crossref
Phornsiri Pechsrichuang & Alain Jacquet. (2020) Molecular approaches to allergen‐specific immunotherapy: Are we so far from clinical implementation?. Clinical & Experimental Allergy 50:5, pages 543-557.
Crossref
Jessika R. Richards & Janice L. Stumpf. (2018) House Dust Mite Sublingual Immunotherapy for Pediatric Patients With Allergic Asthma. Annals of Pharmacotherapy 52:10, pages 1019-1030.
Crossref
Carlo Lombardi, Valerie Melli, Cristoforo Incorvaia & Erminia Ridolo. (2017) Pharmacoeconomics of sublingual immunotherapy with the 5-grass pollen tablets for seasonal allergic rhinitis. Clinical and Molecular Allergy 15:1.
Crossref
G. Mortuaire, J. Michel, J.F. Papon, O. Malard, D. Ebbo, L. Crampette, R. Jankowski, A. Coste & E. Serrano. (2017) Specific immunotherapy in allergic rhinitis. European Annals of Otorhinolaryngology, Head and Neck Diseases 134:4, pages 253-258.
Crossref
G. Mortuaire, J. Michel, J.-F. Papon, O. Malard, D. Ebbo, L. Crampette, R. Jankowski, A. Coste & E. Serrano. (2017) L’immunotherapie antiallergenique dans la rhinite allergique. Annales françaises d'Oto-rhino-laryngologie et de Pathologie Cervico-faciale 134:4, pages 247-253.
Crossref
Glenis K. Scadding & Guy W. Scadding. 2017. The Nose and Sinuses in Respiratory Disorders. The Nose and Sinuses in Respiratory Disorders 193 208 .
Åse Björstad, Lars-Olaf Cardell, Julie Hahn-Pedersen & Mikael Svärd. (2017) A Cost-Minimisation Analysis Comparing Sublingual Immunotherapy to Subcutaneous Immunotherapy for the Treatment of House Dust Mite Allergy in a Swedish Setting. Clinical Drug Investigation 37:6, pages 541-549.
Crossref
Katherine A. Lyseng-Williamson. (2016) Standardized quality house dust mite sublingual tablets (Acarizax®): a guide to their use as sublingual allergy immunotherapy in Europe. Drugs & Therapy Perspectives 32:12, pages 502-509.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.